Novartis

Produktion af lægemidler

Basel, Baselstadt 3.915.107 følgere

Se job Følg

Vis alle 78.002 medarbejdere

Om os

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Websted: http://www.novartis.com
Eksternt link til Novartis
Branche: Produktion af lægemidler
Virksomhedsstørrelse: Over 10.001 medarbejdere
Hovedkvarter: Basel, Baselstadt
Type: Aktieselskab
Specialer: Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand og Gene and cell therapy

Beliggenheder

Primær

Novartis Campus

Basel, Baselstadt 4002, CH

Se ruten
One Health Plaza

East Hanover, NJ 07936, US

Se ruten
Calle 93B S-31

Bogota, Bogota, D.C. 110541, CO

Se ruten
Merrion Road

Dublin, County Dublin, IE

Se ruten
Na Pankraci 1724/129

Prague, Prague 140 00, CZ

Se ruten
Via Espana

Panama City, Panama, PA

Se ruten
Edvard Thomsens Vej 14

Copenhagen, Capital Region 2300, DK

Se ruten
Tirana, AL, AL

Se ruten
Buenos Aires, AR

Se ruten
Macquairie Park, NSW, AU

Se ruten
Wien, AT

Se ruten
Kundl, Tirol, AT

Se ruten
Baku, AZ

Se ruten
Amsterdam, NL

Se ruten
Auckland, NZ

Se ruten
Ikeja, Lagos, NG

Se ruten
Skopje, MK

Se ruten
Oslo, NO

Se ruten
Muscat, OM

Se ruten
Karachi, PK

Se ruten
Ciudad de Panamá, PA

Se ruten
Ciudad de Panamá, PA

Se ruten
Lima, PE

Se ruten
Makati City, PH

Se ruten
Warsaw, PL

Se ruten
Porto Salvo, PT

Se ruten
Cataño, PR

Se ruten
Dhaka, BD

Se ruten
St. Michael, BB

Se ruten
Minsk, BY

Se ruten
Brussels, BE

Se ruten
Sarajevo, BA

Se ruten
Sao Paulo, BR

Se ruten
Sofia, BG

Se ruten
Douala, CM

Se ruten
Quebec, CA

Se ruten
Santiago de Chile, CL

Se ruten
Beijing, CN

Se ruten
Shanghai, CN

Se ruten
Santafe de Bogota, CO

Se ruten
San Jose, CR

Se ruten
Abidjan, CI

Se ruten
Zagreb, HR

Se ruten
Wilemstad, CW

Se ruten
Doha, QA

Se ruten
Bucharest, RO

Se ruten
Ekaterinburg, RU

Se ruten
Kazan, RU

Se ruten
Leshkovo Village, Moscow, RU

Se ruten
Moscow, RU

Se ruten
Novosibirsk, RU

Se ruten
Rostov-on-Don , RU

Se ruten
St. Petersburg, RU

Se ruten
Dammam, SA

Se ruten
Jeddah, SA

Se ruten
Riyadh, SA

Se ruten
Dakar, SN

Se ruten
Novi Beograd, RS

Se ruten
Singapore Country, SG

Se ruten
Bratislava, SK

Se ruten
Ljubljana, SI

Se ruten
Kempton Park, Gauteng, ZA

Se ruten
Seoul, KR

Se ruten
Barcelona, ES

Se ruten
Sardón de Duero / Valladolid, ES

Se ruten
Colombo, LK

Se ruten
Montevideo, UY

Se ruten
Tashkent, UZ

Se ruten
Caracas, VE

Se ruten
Ho Chi Minh City, VN

Se ruten
Lusaka, ZM

Se ruten

Medarbejdere hos Novartis

Se alle medarbejdere

Opdateringer

Novartis

3.915.107 følgere
14t
Rapportér dette indlæg
As we increase our radioligand therapy (RLT) manufacturing footprint, we are intentionally creating space for continued innovation and growth, driven by the opportunities these advancements may present for patients worldwide. #ReimagineMedicine

Novartis US

91.316 følgere
14t

Today we announced the construction of two new radioligand therapy (RLT) manufacturing facilities, one of which will produce critical isotopes necessary to create these medicines. As the leader in RLT development and delivery, we remain committed to pioneering RLT science and broadening manufacturing capabilities to support the growing demand for this novel approach to cancer care.

6 Kommentarer

Synes godt om Kommenter Del
Novartis

3.915.107 følgere
1u Redigeret
Rapportér dette indlæg
At Novartis, we envision a world where preventable cardiovascular deaths are no longer part of our lives. The City Heartbeat Index is being launched today by the World Heart Federation. The Index assessed efforts to understand, prevent and address CVD in 50 cities worldwide, serving as a benchmark for cities on their efforts to protect people’s health. Over half of the world’s population live in cities making this a major step forward to support the development of targeted public health interventions We’re proud to have commissioned the study, independently conducted by Economist Impact. It is by working together, with patients, healthcare professionals, and organizations around the world, that we can have the biggest impact with these learnings. Gain an insight into the key takeaways here and then explore how your city scored: https://lnkd.in/euT4WzFF *Correction: New York = 4/50, Berlin = 5/50

Discover the City Heartbeat Index

9 Kommentarer

Synes godt om Kommenter Del
Novartis

3.915.107 følgere
1md
Rapportér dette indlæg
Our Q2 performance reflects the continued strong momentum of Novartis. Across the company our teams demonstrated strong commercial execution both in the US and internationally. We also advanced our pipeline, completing new FDA submissions and executing multiple deals to expand our pipeline in RLT and prostate cancer. It’s a great time to be at Novartis as we remain on track for the future. https://lnkd.in/gNdZv2pP #NVSQ224

Q2 2024 Results

29 Kommentarer

Synes godt om Kommenter Del
Novartis

3.915.107 følgere
2md Redigeret
Rapportér dette indlæg
Chronic myeloid leukemia (CML) is a type of cancer that affects the blood and bone marrow, where blood cells are made. Recognizing the symptoms of CML is crucial for early detection. These can include fatigue, weight loss, fever, and an enlarged spleen causing discomfort on the left side of the abdomen. Taking proactive steps with your healthcare provider for regular check-ups and monitoring can be beneficial, leading to better disease management and improved quality of life (#QoL). Learn more about CML and its management here: https://lnkd.in/gVRjQiAy

Understanding and managing CML

14 Kommentarer

Synes godt om Kommenter Del
Novartis

3.915.107 følgere
2md
Rapportér dette indlæg
At #EHA24, we are proud to present data from our Phase III ASC4FIRST trial for patients with newly diagnosed chronic myeloid leukemia (#CML). CML is a type of cancer that develops in the blood-forming cells of the bone marrow. Despite 25+ years of innovation in CML, unmet needs still exist as newly diagnosed patients may fail to meet molecular response goals or discontinue or change treatments due to intolerance. Learn more about Novartis commitment to fighting blood cancers: https://lnkd.in/gvzPZJiQ

Unmet need in CML

5 Kommentarer

Synes godt om Kommenter Del
Novartis

3.915.107 følgere
2md
Rapportér dette indlæg
Paroxysmal nocturnal hemoglobinuria (PNH) is a debilitating blood disorder which causes a range of life-limiting symptoms for those affected. We spoke to the Aplastic Anemia and MDS International Foundation (AAMDSIF) to highlight the importance of providing support for patients living with rare diseases Click the link to learn more about AAMDSIF and the strides they are making to improve life for people living with PNH: https://lnkd.in/gZUvmp-T
6 Kommentarer

Synes godt om Kommenter Del
Novartis

3.915.107 følgere
2md
Rapportér dette indlæg
We are proud to share that our study investigating #radioligandtherapy has been selected as Abstract of the Year by Society of Nuclear Medicine and Molecular Imaging (SNMMI), reinforcing its potential for patients in need. #ReimagineMedicine #SNMMI24
16 Kommentarer

Synes godt om Kommenter Del
Novartis

3.915.107 følgere
2md Redigeret
Rapportér dette indlæg
At Novartis, our long-standing commitment to patients living with chronic myeloid leukemia (CML) spans more than two decades, marked by breakthroughs that have helped turn what was once a life-limiting condition into a chronic one for many. Yet, there's more ground to cover. Despite advancements, many patients still face hurdles such as lower response rates, treatment resistance, and intolerance, and have poor quality of life. That’s why we’re committed to continuing to pioneer targeted treatments for CML, and ensuring every patient has access to innovative medicines. Learn more here: https://lnkd.in/gadSYVJg

Pioneering solutions for patients with CML

5 Kommentarer

Synes godt om Kommenter Del
Novartis

3.915.107 følgere
2md
Rapportér dette indlæg
This #EHA24, we are delighted to be sharing new data in paroxysmal nocturnal hemoglobinuria (PNH) - a rare and serious blood disorder. Learn more about our commitment to patients living with PNH: https://lnkd.in/g7_yemU7

Learn more about PNH

1 Kommentar

Synes godt om Kommenter Del
Novartis

3.915.107 følgere
2md Redigeret
Rapportér dette indlæg
Novartis has always been driven by a deep commitment to advancing cancer care while placing patients at the heart of everything we do. Our goal remains clear: to improve patient outcomes and enhance quality of life for individuals worldwide. We continue to explore new avenues in research and development, learn more about how we are reimagining medicine to improve and extend people’s lives: https://lnkd.in/g4wsCMkK

Pioneering the future of cancer care beyond CML

8 Kommentarer

Synes godt om Kommenter Del

Tilknyttede sider

Tilsvarende sider

Aktie

NVS

4. september 2024

NYSE

20 minutters forsinkelse

119,38 US$

0,88 (0,743 %)

Åbningspris: 118,29
Lavpunkt: 118,29
Højdepunkt: 119,425

Data fra Refinitiv

Få flere oplysninger på Bing

Finansiering

Novartis 2 runder i alt

Seneste runde

Post IPO-gæld 19. jul. 2024

2.487.694.394,00 US$

Læs mere på crunchbase

Novartis

Produktion af lægemidler

Basel, Baselstadt 3.915.107 følgere

Om os

Beliggenheder

Medarbejdere hos Novartis

Guy Dickinson

Figuring out #FutureOfWork: GenerativeAi + Employee Experience + Behavioural Design + Capability Building + Digital Skills

David Yee

Head Portfolio Systems, Portfolio Strategy & Analytics, Strategy & Growth at Novartis

Rodolfo Garcia de Alba Cassaigne

Regional Category Procurement Director, US Marketing Agencies

Kelley Dallas Priddy, M.S.

Medical Sales Specialist | Award Winner | Drives Sales Performance Through Analytics & Business Planning

Opdateringer

Discover the City Heartbeat Index

Q2 2024 Results

Understanding and managing CML

Unmet need in CML

Pioneering solutions for patients with CML

Learn more about PNH

Pioneering the future of cancer care beyond CML

Tilmeld dig nu for at se, hvad du går glip af

Tilknyttede sider

Novartis India

Novartis Science

Novartis Brasil

Novartis Italia

Novartis US

Novartis Gene Therapies

Novartis México

Novartis España

Novartis Portugal

Novartis Colombia

Novartis Deutschland

Novartis, Australia & New Zealand

Novartis Canada

Novartis Gulf | نوفارتس الخليج

Novartis in Slovenia

Novartis Argentina

Novartis US Medical

Novartis Ireland

Novartis Singapore

Novartis România

Novartis Czech Republic

Novartis Nederland

Novartis Norge

Novartis Belux

Novartis Danmark

Novartis Sverige

Novartis Slovakia

Novartis Finland

Novartis Magyarország

Novartis Israel

Novartis Serbia

Novartis Medical

Tilsvarende sider

Pfizer

Sanofi

GSK

Roche

AstraZeneca

Johnson & Johnson

Novo Nordisk

Bayer

Abbott

Eli Lilly and Company

Aktie

Finansiering